NASDAQ · PRVB
Healthcare · Biotechnology
$24.98
Up+$0.00 (+0.00%)
Updated Oct 7, 2026, 2:22 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · PRVB
1M range · 0 trading sessions · Daily adjusted prices
PRVB does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning PRVB.
Company
Market Activity
Research & News
PRVB research
Company profile and research snapshot.
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 15, 2023 | HC Wainwright & Co. | Neutral | — |
| Mar 14, 2023 | SMBC Nikko | Neutral | — |
| Mar 14, 2023 | Jefferies | Hold | — |
| Mar 13, 2023 | Chardan Capital | Buy | — |
| Feb 15, 2023 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Zacks Investment Research · Apr 27, 2023
Sanofi (SNY) beats first-quarter estimates for earnings but misses the same for sales. Higher sales of Dupixent and rare disease drugs drive Specialty Care GBU sales.
Zacks Investment Research · Apr 27, 2023
Provention Bio, Inc. (PRVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research · Apr 20, 2023
Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent.
PennyStocks · Apr 6, 2023
Penny stocks for beginners and how to make money trading cheap stocks in 2023 The post Penny Stocks, How To Buy Them & Day Trading Basics For 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PRVB.
No results
No recent SID articles mention PRVB.
